CY1106825T1 - Θεραπεια καρκινων με απλιδινη - Google Patents

Θεραπεια καρκινων με απλιδινη

Info

Publication number
CY1106825T1
CY1106825T1 CY20071101110T CY071101110T CY1106825T1 CY 1106825 T1 CY1106825 T1 CY 1106825T1 CY 20071101110 T CY20071101110 T CY 20071101110T CY 071101110 T CY071101110 T CY 071101110T CY 1106825 T1 CY1106825 T1 CY 1106825T1
Authority
CY
Cyprus
Prior art keywords
aplidine
treatment
cancer
tumors
complementing
Prior art date
Application number
CY20071101110T
Other languages
English (en)
Inventor
Glynn Thomas Faircloth
Chris Twelves
Luis Paz-Ares
Original Assignee
Pharma Mar S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927006.8A external-priority patent/GB9927006D0/en
Priority claimed from GB0005701A external-priority patent/GB0005701D0/en
Priority claimed from GB0007639A external-priority patent/GB0007639D0/en
Priority claimed from GB0015496A external-priority patent/GB0015496D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Application filed by Pharma Mar S.A. filed Critical Pharma Mar S.A.
Publication of CY1106825T1 publication Critical patent/CY1106825T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Η απλιδίνη αποδεικνύεται εξαιρετικά υποσχόμενη στις κλινικές δοκιμασίες φάσης (Ι) για τη θεραπεία όγκων και δίνονται διάφορα θεραπευτικά συστήματα δόσεων. Παρατηρήθηκε μείωση των όγκων σε διάφορους τύπους όγκων μεταξύ των οποίων του καρκινώματος των νεφρών, του καρκίνου του παχέος εντέρου και του ορθού, του καρκινοειδούς όγκου του πνεύμονα, του μυελοειδούς καρκίνου του θυρεοειδούς και του μελανώματος. Ανακαλύφθηκε επίσης ότι η απλιδίνη παίζει κάποιο ρόλο στην αναστολή της αγγειογέννεσης, συμπληρώνοντας την αντιογκική δραστηριότητα.
CY20071101110T 1999-11-15 2007-08-30 Θεραπεια καρκινων με απλιδινη CY1106825T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9927006.8A GB9927006D0 (en) 1999-11-15 1999-11-15 Aplidine treatment of cancers
GB0005701A GB0005701D0 (en) 2000-03-09 2000-03-09 Antitumor utility of aplidine
GB0007639A GB0007639D0 (en) 2000-03-29 2000-03-29 Antitumour and anti-angiogenic compound
GB0015496A GB0015496D0 (en) 2000-06-23 2000-06-23 Antitumour and anti-angiogenic compound
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers

Publications (1)

Publication Number Publication Date
CY1106825T1 true CY1106825T1 (el) 2012-05-23

Family

ID=27515929

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101110T CY1106825T1 (el) 1999-11-15 2007-08-30 Θεραπεια καρκινων με απλιδινη

Country Status (27)

Country Link
US (1) US20090298752A1 (el)
EP (1) EP1229922B1 (el)
JP (1) JP2003514025A (el)
KR (1) KR100518986B1 (el)
CN (1) CN1423564A (el)
AT (1) ATE363910T1 (el)
AU (1) AU780417B2 (el)
BG (1) BG65381B1 (el)
BR (1) BR0015811A (el)
CA (1) CA2391502A1 (el)
CY (1) CY1106825T1 (el)
CZ (1) CZ302498B6 (el)
DE (1) DE60035120T2 (el)
DK (1) DK1229922T3 (el)
ES (1) ES2288486T3 (el)
HK (1) HK1045648B (el)
HU (1) HUP0203906A2 (el)
IL (1) IL149488A0 (el)
MX (1) MXPA02004862A (el)
NO (1) NO330719B1 (el)
NZ (1) NZ518847A (el)
PL (1) PL200922B1 (el)
PT (1) PT1229922E (el)
RU (1) RU2261104C2 (el)
SI (1) SI1229922T1 (el)
SK (1) SK287762B6 (el)
WO (1) WO2001035974A2 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CN1479622A (zh) 2000-10-12 2004-03-03 联合使用阿普里汀和肌肉保护剂来治疗癌症
WO2003033013A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
DK1603584T3 (da) * 2003-03-12 2009-01-05 Dana Farber Cancer Inst Inc Aplidine til behandling af multipelt myelom
RU2341283C2 (ru) * 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
PL2029155T3 (pl) * 2006-02-28 2016-09-30 Ulepszony sposób leczenia szpiczaka mnogiego
EP2117539B1 (en) * 2006-11-03 2010-09-01 Nerviano Medical Sciences S.r.l. A method of administering an antitumor compound
CA2703024A1 (en) * 2007-10-19 2009-04-23 Giuseppe Longo Sorbello Improved antitumoral treatments
KR20100131474A (ko) * 2008-03-07 2010-12-15 파르마 마르 에스.에이. 개선된 항암치료
CN103463020B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗肾癌药物中的应用
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
DE3161556D1 (en) * 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
EP0220453B1 (de) * 1985-09-20 1992-04-15 Cernitin S.A. Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
CA2180260A1 (en) * 1993-12-29 1995-07-06 Dennis M. Brown Methods and compositions for the treatment of a host with a cellular proliferative disease
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6030943A (en) * 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CA2405779A1 (en) * 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US7175849B2 (en) * 2000-10-05 2007-02-13 Immunex Corporation Nectin polypeptides
CN1479622A (zh) * 2000-10-12 2004-03-03 联合使用阿普里汀和肌肉保护剂来治疗癌症
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US6610399B1 (en) * 2000-11-17 2003-08-26 Structural Technologies, Llc Multi-layer, thermal protection and corrosion protection coating system for metallic tendons, especially for external post-tensioning systems
WO2003033013A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
DK1603584T3 (da) * 2003-03-12 2009-01-05 Dana Farber Cancer Inst Inc Aplidine til behandling af multipelt myelom
RU2341283C2 (ru) * 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
WO2004084812A2 (en) * 2003-03-21 2004-10-07 Joullie Madeleine M Tamandarin analogs and fragments thereof and methods of making and using
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
PL2029155T3 (pl) * 2006-02-28 2016-09-30 Ulepszony sposób leczenia szpiczaka mnogiego
CA2703024A1 (en) * 2007-10-19 2009-04-23 Giuseppe Longo Sorbello Improved antitumoral treatments

Also Published As

Publication number Publication date
ATE363910T1 (de) 2007-06-15
CZ20021697A3 (cs) 2003-02-12
NO20022293D0 (no) 2002-05-14
DE60035120T2 (de) 2008-01-31
SK287762B6 (sk) 2011-09-05
US20090298752A1 (en) 2009-12-03
NO330719B1 (no) 2011-06-20
BG65381B1 (bg) 2008-05-30
PT1229922E (pt) 2007-09-12
MXPA02004862A (es) 2003-01-28
SI1229922T1 (sl) 2008-04-30
NZ518847A (en) 2004-02-27
CZ302498B6 (cs) 2011-06-15
HK1045648A1 (en) 2002-12-06
HUP0203906A2 (en) 2003-03-28
IL149488A0 (en) 2002-11-10
JP2003514025A (ja) 2003-04-15
PL355335A1 (en) 2004-04-19
KR20020064313A (ko) 2002-08-07
EP1229922A2 (en) 2002-08-14
KR100518986B1 (ko) 2005-10-06
AU1402301A (en) 2001-05-30
EP1229922B1 (en) 2007-06-06
DE60035120D1 (de) 2007-07-19
DK1229922T3 (da) 2007-10-08
HK1045648B (zh) 2007-09-21
AU780417B2 (en) 2005-03-17
SK6592002A3 (en) 2003-08-05
RU2002115864A (ru) 2004-01-20
RU2261104C2 (ru) 2005-09-27
WO2001035974A2 (en) 2001-05-25
PL200922B1 (pl) 2009-02-27
BG106714A (en) 2003-02-28
CA2391502A1 (en) 2001-05-25
ES2288486T3 (es) 2008-01-16
NO20022293L (no) 2002-07-05
CN1423564A (zh) 2003-06-11
WO2001035974A3 (en) 2001-11-01
BR0015811A (pt) 2002-08-06

Similar Documents

Publication Publication Date Title
CY1106825T1 (el) Θεραπεια καρκινων με απλιδινη
ATE399560T1 (de) Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von nicht-hodgkihn- lymphome
CY1114730T1 (el) Ανοσοσυζευγματα για τη θεραπεια των ογκων
CY1118316T1 (el) Θεραπεια συμπαγων νεφρικων ογκων με ενα παραγωγο ραπαμυκινης
CY1114040T1 (el) Συνδυαστικη θεραπεια του καρκινου περιλαμβανουσα αναστολεις των egfr/her2
CY2013020I2 (el) Η χρηση μιας ενωσης ινγκενανης για την κατασκευη ενος φαρμακου για την θεραπεια του καρκινου
ATE274357T1 (de) Texaphyrin-konjugate und ihre anwendiung
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
IS6375A (is) Lyfjagjöf til öftrunar á blöðruhálskrabbameini
AR029763A1 (es) Uso de una combinacion de una nsaid y un inhibidor de quinasa egfr para la manufactura de un medicamento para el tratamiento o inhibicion de polipos colonicos y cancer colorectal, composicion farmaceutica y medicamento
BR9814059A (pt) Composto, composição farmacéutica, e, processos para tratamento de um indivìduo com câncer de mama ou de próstata, para inibir o crescimento de células tumorais da mama ou da próstata, e, para induzir a apoptose de células tumorais da mama ou da próstata
TR199800270T1 (xx) Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
TR200001687T2 (tr) Neopleasyo için N-benzil-3-indenilasetamid türevleri.
DE60141194D1 (de) Behandlung des metastasierenden Karzinoms der Niere
CY1105189T1 (el) Χρηση συνδυασμου που πepιεχει 4-πυριδυλομεθυλοφθαλαζινες για τη θepαπεια του καρκινου
CY1105392T1 (el) Μεσο με καταστρεπτικη δραση σε κακοηθεις ογκους και μεθοδος για την παραγωγη του
BG108932A (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
Singh et al. Coordination-driven self-assembly of triazole-based apoptosis-inducible metallomacrocycles
DE69807166D1 (de) Prostata-spezifische Antigen Inhibitore